About
About this Poster:
Despite NAFLD/NASH being a prevalent co-morbidity in obesity and type 2 diabetes, the clinical development of NAFLD/NASH therapeutics is currently hindered by significant challenges in clinical trial enrollment. Traditional study screening is commonly associated with screen failure rates of >90%. Given the cost- and timeline implications of subjects failing to meet MRI- or biopsy-based inclusion criteria, there is a clear need for optimized screening strategies in NAFLD/NASH clinical studies.
